The U.S. Autism Treatment Market is Expected to Reach $2.23 Billion by 2022 - ResearchAndMarkets.com

DUBLIN--()--The "The U.S. Autism Treatment Market" report has been added to ResearchAndMarkets.com's offering.

The U.S. autism treatment market was estimated to be valued at $1.85 billion as of 2016, growing to $1.87 billion last year. 3.9% average yearly growth is forecasted, to reach $2.23 billion by 2022. This could be conservative, as insurance coverage is improving. In addition, venture capital firms are starting to take notice of investment opportunities in this market.

The average ABA center grosses about $821,000, and many are non-profit organizations. Many programs now have waiting lists and there is a shortage of qualified supervisors.

Nine large multi-site ABA program providers operate an estimated 296 brick & mortar centers and employ thousands of therapists. Together, they account for about $390 million in revenues - a 38% market share of ABA programs.

Revenues of ABA (applied behavioral analysis) programs are estimated to generate $1.07 billion in revenues this year, outpacing sales of prescription drugs used for autism symptoms.

The incidence of autism among American children has soared from 1 in 150 in 2000 to 1 in 45 today, and 2.1 million children and adults now live with autism. Yet, few therapies exist to treat this disease - just a few medications and ABA (applied behavioral analysis) programs. This is a fragmented $1.8 billion market comprised of for-profit and non-profit providers that serve autistic patients via brick & mortar centers and in-home therapy provided by therapists. Waiting lists are growing and only 36% of patients are estimated to have access to insurance coverage.

The report includes: dollar value & growth of the market from 2009 to a 2022 forecast, market structure, key metrics of treatment centers, definition of and the types of autism, typical therapies used, how ABA programs work, insurance coverage, patient demographics, analysis of the market for drugs to treat autism (Risperdal, Abilify, Ritalin), latest CDC research findings on autism, market growth factors, economic costs, and a ranking of the top treatment chains/no. of centers. It also contains 11 in-depth competitor profiles and revenues of the largest players in the field.

Companies Mentioned

  • Autism Learning Partners
  • Autism Speaks
  • Autism Spectrum Therapies
  • Butterfly Effects
  • Centria Autism Services
  • Chance Light Behavioral Health
  • City Pro Group
  • The Center for Autism & Related Disorders
  • The May Institute
  • UPMC

For more information about this report visit https://www.researchandmarkets.com/research/lvtkj6/the_u_s_autism?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs